|
|
 |
|
Viewing report
|
|
|
|
Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Oct 2011, Pages: 84
Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global SLE market. The report identifies the key trends shaping and driving the global SLE market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SLE sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated the global (the US, the UK, France, Germany, Italy, Spain and Japan) systemic lupus erythematosus (SLE) therapeutics market to be worth $256m in 2010 and projects it to grow at a compound annual growth rate (CAGR) of 24.7% to reach $1.6 billion in 2018. Benlysta (belimumab) was approved on March 9, 2011 by the US Food and Drug Administration (FDA) and on July 14, 2011 by the European Medicine Evaluation Agency (EMEA) in Europe for treating adult patients with active, autoantibody-positive SLE. It the drug for SLE to be approved in 50 years and is expected to drive the SLE market in the near future. Furthermore, the entry of four first-in-class (FIC) biologics, Orencia (abatacept), atacicept, epratuzumab, LY2127399 is expected to play a major role in the expansion of the SLE market by 2018.
Scope
The report provides information on the key drivers and challenges of the SLE market. Its scope includes -
- Annualized seven key SLE market (US, France, Germany, Italy, Spain, UK and Japan) revenue data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under the following major therapeutic classes: anti-BAFF (B-cell activating factor), immunomodulator, anti-IFN-alpha, Toll-Like Receptor TLR7/TLR9 inhibitor, CD22 antigen Inhibitor, T-cell co-stimulation modulator and calcineurin inhibitor.
- Analysis of the current and future competition in the global SLE market. Key market players covered are Anthera Pharma, AstraZeneca PLC/MedImmune LLC, Active Biotech AB, Amgen Inc., Bristol-Myers Squibb Co., Biotest AG, Cephalon, Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd/Genentech, Johnson & Johnson/Centocor, Inc, Merck KGaA/Merck Sereno, MedImmune, LLC, Neovacs SA, Onyx Pharmaceuticals and UCB Group/Immunomedics Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet need and the implications for the SLE therapeutics market.
- Analysis of key recent licensing and partnership agreements in the SLE market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global SLE market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global SLE market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What is the next big thing in the global SLE market landscape? Identify, understand and capitalize.
|
|
|
|
